F2G is a clinical-stage biopharmaceutical company focused on the discovery & development of novel therapies to treat life-threatening invasive fungal infection.
New Jersey
- Tweets 89
- Following 125
- Followers 55
- Likes 1
FOR INVESTORS & MEDIA ONLY
Today at @IDWeekmtg, we’re presenting Phase 3 data, generated in collaboration with Shionogi & Co., Ltd., in invasive aspergillosis.
View the press release: bit.ly/4a3jvSg
#IDWeek2026
60
At @IDWeekmtg we will be exchanging information with colleagues on abstracts we have created for invasive fungal disease.
Learn more about the conference: bit.ly/4j7PzK4
#IDWeek2026
41
Our CEO, Francesco Maria Lavino, & CFO, Ralf Schimid, will participate in Canaccord Genuity’s 2026 Biotech Private Company Symposium, bringing together private biotech companies across multiple therapeutic areas. Learn more: bit.ly/3TCxw4l
#CGDriven #DrivenByYourSuccess
17
Serious fungal infections can be difficult to treat, with challenges including resistance, breakthrough infections and drug-drug interactions.
Where is innovation most needed in antifungal care?
Cast your vote below and learn more: f2g.com/fungal-landscape/
0%
Novel mechanisms
0%
Addressing resistance
0%
Safety & tolerability
0%
Treatment flexibility
0 votes • Final results
10
We look forward to connecting with the infectious disease community & sharing research findings at @IDWeekmtg #IDWeek2026. We’ll present Phase 3 data in a late-breaking oral presentation & two posters at this year’s meeting. See details in press release: bit.ly/4a3jvSg
49
Antifungal resistance is on the rise. Our CMO John Rex, MD, discusses why developing new antifungal medicines is uniquely challenging and the need for continued innovation to address the evolving fungal landscape.
Read more: bit.ly/4A1LdKz
#AntifungalResistance
15
As Fungal Disease Awareness Week comes to a close, awareness of fungal diseases remains important year-round. From antifungal resistance to challenges in diagnosis and treatment, there is more work to be done.
Learn more from the CDC: bit.ly/4dyCy6u
#ThinkFungus26
13
This Fungal Disease Awareness Week, we're shining light on the need for novel antifungal treatments. Infectious disease experts discuss gaps in the current treatment landscape and what is on the horizon.
Learn more: bit.ly/4xENk5t
#ThinkFungus
12
Invasive fungal infections can be difficult to treat, particularly as antifungal resistance grows and more patients become vulnerable to serious fungal disease.
Learn more about the challenges shaping the fungal landscape: bit.ly/4fbRMAl
12
At #MSGERC2026, Fariba Donovan, MD, PhD, and F2G’s Daniela Zinzi will present posters highlighting serious fungal infections and unmet treatment needs.
F2G is proud to sponsor this year’s meeting.
Learn more: bit.ly/4i792tT
22
We look forward to sharing research at two upcoming meetings:
•MSGERC 2026 Biennial Meeting | Sept. 9–11 | Denver
•ISPOR Europe 2026 | Nov. 8–11 | Vienna
We’ll present posters highlighting serious fungal infections & unmet treatment needs. More here: bit.ly/3G2zPXy
17
We are proud to sponsor the @MSG_ERC 2026 Biennial Meeting, taking place in Denver. We look forward to connecting with the infectious disease community and supporting knowledge exchange and collaboration to address fungal infections. Learn more: bit.ly/4baUwNm
15
Recent dust storms across the southwestern U.S. are bringing renewed attention to #ValleyFever, caused by breathing in Coccidioides spores found in soil and dust. Know the signs, including fatigue, cough, fever, headache, & shortness of breath. Learn more: bit.ly/4vK4nRx
20
We’re proud to sponsor the 8th International Coccidioidomycosis Study Group Symposium. We remain committed to supporting antifungal innovation through knowledge exchange, scientific collaboration, & dialogue in the infectious disease community. More here: bit.ly/4wn3vU4
15
The fungal landscape is changing. Antifungal resistance, environmental shifts, and a growing population of immunocompromised patients are reshaping the challenge of serious fungal infections. Learn more: bit.ly/4fbRMAl
16
Did you know that people with weakened immune systems are at increased risk of #InvasiveAspergillosis? At F2G, we're committed to advancing therapies and raising awareness of serious fungal diseases.
Learn more about IA: bit.ly/4vU1vT8
16
Join us today at #BIO2026 for a panel discussion “Will Fungi Be the Last of Us? Reviving Infectious Disease Innovation” as we explore the fungal threat and approaches needed to accelerate innovation and stay ahead. Learn more: bit.ly/4wetNs6
2
107
We’re pleased to announce the topline data from our Phase 3 study conducted in collaboration with Shionogi & Co. in patients with invasive fungal disease. Visit our website to view our press release: f2g.com/media/
FOR INVESTORS & JOURNALISTS ONLY
1
3
89
This National Safety Month, we're raising awareness about #ValleyFever, a fungal disease linked to inhaling airborne spores from disturbed soil. Prevention starts with awareness. Learn more: bit.ly/4vhGlOC
#NSM
21
Could The Last of Us become more than fiction? Fungal pathogens are evolving & becoming harder to treat. At #BIO2026 we are discussing growing challenges of fungal disease & the need to stay ahead of new threats.
📅 June 22 | 🕒 3:00 PM–4:00 PM
Learn more: bit.ly/4wetNs6
26